G100 + Pembrolizumab + Rituximab
Phase 1/2Terminated 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Follicular Low Grade Non-Hodgkin's Lymphoma
Conditions
Follicular Low Grade Non-Hodgkin's Lymphoma
Trial Timeline
Feb 3, 2016 → Aug 1, 2019
NCT ID
NCT02501473About G100 + Pembrolizumab + Rituximab
G100 + Pembrolizumab + Rituximab is a phase 1/2 stage product being developed by Merck for Follicular Low Grade Non-Hodgkin's Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT02501473. Target conditions include Follicular Low Grade Non-Hodgkin's Lymphoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02501473 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Follicular Low Grade Non-Hodgkin's Lymphoma